Posaconazole Intravenous (IV) Solution bulk supplier for pharma manufacturers

Posaconazole Intravenous (IV) Solution Suppliers & Bulk Manufacturers

Available Forms: Intravenous (IV) solution

Available Strengths: 300 mg/16.7 mL (18 mg/mL) vial

Reference Brands: Noxafil(US & EU)

Posaconazole intravenous solution, 300 mg, a triazole antifungal for hospital use when oral therapy is not possible. Listed for hospital pharmacies, importers and tender buyers with cold-chain capability.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Posaconazole Intravenous (IV) Solution? List it or send an offer →

Product Description:

Posaconazole is a triazole antifungal. It inhibits lanosterol 14-alpha-demethylase, a fungal cytochrome P450 enzyme needed to make ergosterol, so the fungal cell membrane fails. The intravenous form serves patients who cannot take or absorb oral medicines. Because posaconazole barely dissolves in water, the IV product uses a cyclodextrin solubiliser. This page covers the widely registered presentation, a 300 mg concentrate in a 16.7 mL vial that is diluted before infusion.

Posaconazole IV is used to prevent invasive Aspergillus and Candida infections in high-risk patients, such as stem cell transplant recipients with graft-versus-host disease or people with prolonged neutropenia from blood cancer treatment, and to treat invasive aspergillosis. The usual dose is 300 mg twice on day 1, then 300 mg daily, infused over about 90 minutes through a central line. The cyclodextrin can build up in moderate or severe kidney impairment. Posaconazole strongly inhibits CYP3A4: sirolimus, ergot alkaloids and some statins are contraindicated, and tacrolimus or ciclosporin doses are reduced.

Sourcing notes. Posaconazole IV is a hospital product, ordered mainly by haematology, transplant and intensive care pharmacies. Vials of concentrate are stored at 2-8 °C, so agree cold-chain shipping and storage in writing, and check the label of any ready-to-use presentation. Expect a CTD or ACTD dossier with data on the cyclodextrin excipient and compatibility with approved diluents. Ask for a CoA per batch, the sterile manufacturing GMP certificate and a CoPP. State presentation, quantity, shelf life at delivery and whether oral forms are needed for step-down.

Posaconazole Intravenous (IV) Solution — third party manufacturing & bulk supply

Posaconazole Intravenous (IV) Solution is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Posaconazole Intravenous (IV) Solution is supplied as Intravenous (IV) solution — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Posaconazole Intravenous (IV) Solution listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Posaconazole Intravenous (IV) Solution →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Posaconazole is used to prevent and treat serious fungal infections, particularly in immunocompromised patients such as those with hematologic malignancies or stem-cell transplants. It is effective against invasive aspergillosis, mucormycosis, and infections caused by Candida species. It is commonly used when patients cannot tolerate or do not respond to other antifungal therapies.

Posaconazole contains the active triazole antifungal compound posaconazole. The formulation includes pharmaceutical excipients that enhance absorption and maintain stability, depending on the dosage form used.

The main trade name for posaconazole is Noxafil, recognized in the USA, EU, UK, and many international markets.

Noxafil (posaconazole) is manufactured by Merck & Co. Generic versions may also be produced by other GMP-certified pharmaceutical companies in different regions.

The generic name is posaconazole.

The primary brand name is Noxafil.

Posaconazole is manufactured in Merck’s regulated facilities located in the USA and Europe, along with various GMP-approved global manufacturers producing generic posaconazole for international distribution.